EICHOR ● Not Yet Recruiting

Continued Access to Avutometinib in Combination With Defactinib in Patients With Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)

Condition: Low Grade Ovarian Serous Adenocarcinoma · Ovarian Cancer · Sponsor: Verastem, Inc.

PhasePhase 2

Planned participants2

Who can joinFemale, 18 Years to no upper limit

Healthy volunteersNo

About this study

This Open-Label Extension (OLE) study provides participants with recurrent low-grade serous ovarian cancer (LGSOC) who have completed the VS-6766-201(RAMP-201) study continued, uninterrupted access to avutometinib in combination with defactinib. The study is designed to support patients in France with access to avutometinib and defactinib who maintain ongoing clinical benefit while collecting safety and tolerability data during extended treatment. Participation is restricted to patients transferring directly from VS-6766-201(RAMP-201), ensuring continuity of care without enrollment of new patients.

This description comes directly from the study's public registry record.

Talk to the study team

Verastem Call Center · 781-292-4204 · clinicaltrials@verastem.com

Always discuss trial participation with your own doctor first.

Locations (2)

Centre Leon Berard	Lyon, France	—
Institut Curie	Paris, France	—

Sponsor or site team? See the site landscape for this trial — listed sites, countries, and recruiting-density context.

Follow this study

Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.

We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →